75 related articles for article (PubMed ID: 579476)
1. [Clinical and hormonal development of a case of malignant exophthalmus after hypophyseal myskiotomy].
Stoica T; Arseni C; Constantinescu A; Coculescu M; Balmeş E
Endocrinologie; 1977; 15(4):283-8. PubMed ID: 579476
[TBL] [Abstract][Full Text] [Related]
2. [Long-acting thyroid stimulator (LATS), thyrotropin (TSH) and the pathogenesis of hyperthyroidism].
Lamberg BA; Gordin A
Nord Med; 1968 Dec; 80(49):1651-7. PubMed ID: 5757398
[No Abstract] [Full Text] [Related]
3. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
Sawhney RC; Kannan V; Rastogi GK
J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
[No Abstract] [Full Text] [Related]
4. [LATS and Graves' disease].
Gordon A
Harefuah; 1971 May; 80(10):569-70. PubMed ID: 5171988
[No Abstract] [Full Text] [Related]
5. The long-acting thyroid stimulatory: is it of importance in Graves' disease.
McKenzie JM; Zakarija M; D'Amour P; Joasoo A
N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442
[No Abstract] [Full Text] [Related]
6. Abnormalities of hypothalamo-hypophyseal-thyroid axis in patients with Graves' ophthalmopathy.
Chopra IJ; Chopra U; Orgiazzi J
J Clin Endocrinol Metab; 1973 Dec; 37(6):955-67. PubMed ID: 4201831
[No Abstract] [Full Text] [Related]
7. Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.
Ginsberg J; von Westarp C
CMAJ; 1986 May; 134(10):1141-7. PubMed ID: 2421862
[TBL] [Abstract][Full Text] [Related]
8. Graves' disease in patients with 22q11.2 deletion.
Kawame H; Adachi M; Tachibana K; Kurosawa K; Ito F; Gleason MM; Weinzimer S; Levitt-Katz L; Sullivan K; McDonald-McGinn DM
J Pediatr; 2001 Dec; 139(6):892-5. PubMed ID: 11743521
[TBL] [Abstract][Full Text] [Related]
9. Plasma LATS and thyroid antibody level, and the clinical manifestations of Graves' disease.
Földes J; Takó J; Bános C; Gesztesi E; Varga I
Acta Med Acad Sci Hung; 1969; 26(3):233-43. PubMed ID: 5395883
[No Abstract] [Full Text] [Related]
10. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
Bayer MF; Kriss JP; McDougall IR
J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
[TBL] [Abstract][Full Text] [Related]
11. [The effect of immunosuppressive therapy on the long acting thyroid stimulator (LATS) and the clinical picture in patients with localized myxedema and exophthalmus].
Depisch D; Höfer R; Schatz H
Wien Klin Wochenschr; 1969 Jan; 81(1):8-10. PubMed ID: 5818436
[No Abstract] [Full Text] [Related]
12. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
13. Concepts of pathogenesis of Graves' disease.
Solomon DH; Kleeman KE
Adv Intern Med; 1977; 22():273-99. PubMed ID: 402796
[No Abstract] [Full Text] [Related]
14. [Regulation mechanisms of the pituitary-thyroid axis in normal subjects and patients with Graves' disease using a highly sensitive TSH assay].
Takagi S; Yamauchi K; Mori Y; Tanaka H; Miura Y; Takatsuki K; Tomita A; Funahashi H; Mizuno S; Ishizuki Y
Kaku Igaku; 1986 Aug; 23(8):1043-53. PubMed ID: 3784128
[No Abstract] [Full Text] [Related]
15. Familial incidence of long-acting thyroid stimulator (LATS) in Graves' disease.
Bonnyns M; Vanhaelst L
Horm Metab Res; 1972 Mar; 4(2):132. PubMed ID: 5067566
[No Abstract] [Full Text] [Related]
16. Relationships among immunoglobulin markers in Graves' disease.
Ozawa Y; Maciel RM; Chopra IJ; Solomon DH; Beall GN
J Clin Endocrinol Metab; 1979 Mar; 48(3):381-7. PubMed ID: 581874
[No Abstract] [Full Text] [Related]
17. [Standardization of the radiobiological method for determination of long-acting thyroid stimulator (LATS) in human serum].
Muramoto E; Nicolau W; Ikeda E; de Assis LM; Pieroni RR
AMB Rev Assoc Med Bras; 1972 Oct; 18(10):379-88. PubMed ID: 4539360
[No Abstract] [Full Text] [Related]
18. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
Hardisty CA; Fowles A; Munro DS
J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
[TBL] [Abstract][Full Text] [Related]
19. [Simultaneous determination of thyrotropic hormone and long-acting thyroid stimulator in the plasma of patients with Graves' disease].
Földes J; Gesztesi E; Takács I
Klin Wochenschr; 1971 May; 49(9):554-7. PubMed ID: 4102376
[No Abstract] [Full Text] [Related]
20. Cause of increased plasma concentration of iodotyrosines in Graves' disease.
Földes J; Takó J; Bános C; Gesztesi E; Varga I
J Endocrinol; 1970 Mar; 46(3):291-6. PubMed ID: 5467564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
